Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22423851 | 1.00 | SMPD1 (0.42) | SMPD1L3MBTL1HPGDSLC6A4MAPK1 | |
| SCHEMBL19380922 | 0.93 | SMPD1 (0.39) | SMPD1L3MBTL1HPGDSLC6A4MAPK1 | |
| SCHEMBL19359166 | 0.84 | MPO (0.46) | KMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL19359353 | 0.79 | MPO (0.48) | SMPD1L3MBTL1HPGDSLC6A4MAPK1 | |
| SCHEMBL19359467 | 0.73 | LMNA (0.52) | MAPK1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL7351155 | 0.70 | KCNH2 (0.58) | HPGDSLC6A4KMT2AABCB1 | |
| SCHEMBL22406388 | 0.70 | MPO (0.52) | SMPD1L3MBTL1HPGDSLC6A4MAPK1 | |
| SCHEMBL19380923 | 0.68 | MPO (0.49) | SMPD1HPGDSLC6A4MAPK1MC5R | |
| SCHEMBL19359266 | 0.68 | POLB (0.42) | L3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20495649 | 0.68 | HPGD (0.69) | SMPD1L3MBTL1HPGDMAPK1MC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL MYERS SQUIBB CO (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161145-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291016-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE AND/OR EPX | EPX, MPO, SERPINB1 | SMPD1 263/4885L3MBTL1 4421/4885HPGD 231/4885 |
| US-11008317-B2 | Triazolopyridine inhibitors of myeloperoxidase and/or EPX | EPX, MPO, SERPINB1 | SMPD1 263/4885L3MBTL1 4421/4885HPGD 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.